2. Signaling Pathways
  3. GPCR/G Protein
    MAPK/ERK Pathway
  4. Ras

Ras

Ras

Related Products

PDF 2.6 MB

Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.

Ras Isoform Specific Products:

Ras Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-179403
    KRASG12C IN-17
    		Inhibitor
    KRASG12C IN-17 is an orally active covalent KRASG12C inhibitor, showing strong inhibitory activity in KRASG12C-mutant cancer cells (NCI-H23 IC50 = 0.7 nM; NCI-H358 IC50 = 0.5 nM). KRASG12C IN-17 covalently and irreversibly binds to KRASG12C with > 96% modification efficiency in both GDP-bound and GMPPNP-bound conformations. KRASG12C IN-17 can be used for studies of KRAS-driven cancers, including colorectal cancer.
    KRASG12C IN-17
  • HY-143588
    KRAS G12C inhibitor 35
    		Inhibitor
    KRAS G12C inhibitor 35 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 35 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent CN112920183A, compound 3).
    KRAS G12C inhibitor 35
  • HY-153944
    KRAS G12C inhibitor 60
    		Inhibitor
    KRAS G12C inhibitor 60 (compound 23) is a Kras-G12C inhibitor. KRAS G12C inhibitor 60 can be used for the research of lung cancer, colorectal cancer, pancreatic cancer.
    KRAS G12C inhibitor 60
  • HY-P1382
    Rac1 Inhibitor W56
    		Inhibitor
    Rac1 Inhibitor W56 is a peptide containing residues 45-60 of Rac1. Rac1 Inhibitor W56 inhibits Rac1 interaction with guanine nucleotide exchange factors TrioN, GEF-H1, and Tiam.
    Rac1 Inhibitor W56
  • HY-142481
    KRAS G12C inhibitor 30
    		Inhibitor
    KRAS G12C inhibitor 30 is a KRAS G12C inhibitor extracted from patent WO2021252339A1, compound 2. KRAS G12C inhibitor 30 can be used for the research of cancer.
    KRAS G12C inhibitor 30
  • HY-163582
    PROTAC SOS1 degrader-7
    		Inhibitor
    PROTAC SOS1 degrader-7 (Example 15) is a SOS1 PROTAC degrader. PROTAC SOS1 degrader-7 has anti-tumor activity . (Pink: SOS1 ligand (HY-163583); Black: linker (HY-163584); Blue: E3 ligase ligand (HY-W454906)).
    PROTAC SOS1 degrader-7
  • HY-185217
    PPI stabilizer-1
    PPI stabilizer-1-1 (Compound 2) is a KRAS dimerizing agent. PPI stabilizer-1-1 dimerizes KRAS with a KD of 3.8 µM. PPI stabilizer-1-1 co-crystallizes with GCP-KRASG12D. PPI stabilizer-1 can be used for the research of KRAS-driven cancers.
    PPI stabilizer-1
  • HY-112494
    KRas G12C inhibitor 4
    		Inhibitor
    KRas G12C inhibitor 1 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1.
    KRas G12C inhibitor 4
  • HY-P2360A
    G12 TFA
    G12 (Ras 5-17) TFA is a wild-type Ras peptide consisted of amino acids 5-17 (KLVVVGAGGVGKS). G12 TFA can be used as a control of mutant Ras peptides studies (such V12).
    G12 TFA
  • HY-181913
    KRAS G12C-IN-76
    		Inhibitor
    KRAS G12C-IN-76 (Compound 39) is an orally active KRASG12C inhibitor. KRAS G12C-IN-76 inhibits the phosphorylation of ERK. KRAS G12C-IN-76 exhibits anticancer activity against pancreatic cancer.
    KRAS G12C-IN-76
  • HY-168056
    KRAS ligand 5
    		Degrader
    KRAS ligand 5 is the target protein ligand for PROTAC K-Ras Degrader-3 (HY-168054). PROTAC K-Ras Degrader-3 can specifically degrade KRAS mutated proteins.
    KRAS ligand 5
  • HY-175025
    CH091138
    		Degrader
    CH091138 is a potent and selective KRASG12D PROTAC degrader with DC50s of 148.3 nM in HeLa cells and 469.8 nM in AsPC-1 cells. CH091138 selectively degrades exogenous and endogenous KRASG12D but not KRASWT or other KRAS mutants (G12C/G12S/G12V), depending on the VHL-mediated ubiquitin-proteasome system. CH091138 exhibits potent anti-tumor activity and induces cancer cell apoptosis. CH091138 can be used for the studies of pancreatic cancer and colon cancer. (Pink: KRASG12D ligand (HY-175144); Blue: VHL E3 ligase ligand (HY-138678); Black: Linker; VHL E3 ligase ligand + Linker (HY-136006B)).
    CH091138
  • HY-P3129
    KRAS G13D peptide, 25 mer
    KRAS G13D peptide, 25 mer, a KRAS activating oncogene mutation peptide, is an immune potentiator extracted from patent WO2018144775A1. KRAS G13D peptide, 25 mer can be used to prepare KRAS vaccine.
    KRAS G13D peptide, 25 mer
  • HY-167768
    SOS1 activator 2
    SOS1 activator 2 (Compound 65) is a benzimidazole derivative and a SOS1 activator. SOS1 activator 2 has a high binding affinity for SOS1 with a Kd of 9 nM. SOS1 activator 2 can regulate the Ras-ERK signaling pathway, which can be used in the study of cancer.
    SOS1 activator 2
  • HY-161234
    KRAS ligand 3
    		Ligand
    KRAS ligand 3 (compound 1) is BTX-6654 target-binding ligand that can bind KRAS inhibitor and diaplay synergistic tumor growth inhibiton.
    KRAS ligand 3
  • HY-144965
    SOS1-IN-12
    		Inhibitor
    SOS1-IN-12 is a potent son of sevenless homolog 1 (SOS1) inhibitor with a Ki of 0.11 nM for SOS1 and an IC50 of 47 nM for pERK. SOS1-IN-13 can be used for researching anticancer.
    SOS1-IN-12
  • HY-168716
    SOS1-IN-17
    		Inhibitor
    SOS1-IN-17 (Compound 8d) is an orally active inhibitor for SOS1-KRASG12C interaction with an IC50 of 5.1 nM. SOS1-IN-17 inhibits ERK phosphorylation in DLD-1 cell with an IC50 of 18 nM. SOS1-IN-17 exhibits anti-proliferative activity in KRASG12C mutated Mia-Paca-2 cell with an IC50 of 0.11 μM. SOS1-IN-17 exhibits antitumor efficacy against pancreatic cancer in mouse model.
    SOS1-IN-17
  • HY-113793
    BPH-742
    BPH-742 (compound 9) is a Geranylgeranyl diphosphate synthase inhibitor with IC50 of 0.1 μM. BPH-742 has antitumor activity.
    BPH-742
  • HY-179702
    KD36
    		Inhibitor
    KD36 is a selective KRAS-G12C inhibitor with an IC50 value of 0.92 μM. KD36 can inhibit the phosphorylation of ERK and AKT, induce the accumulation of reactive oxygen species (ROS), reduce mitochondrial membrane potential, thereby leading to apoptosis of KRAS-G12C mutant cells. KD36 can be used in the research of non-small cell lung cancer (NSCLC).
    KD36
  • HY-161450
    LHF418
    		Inhibitor
    LHF418 is an effective SOS1 PROTAC degrader with a DC50 value of 209.4 nM in A549 cells. LHF418 can effectively inhibit RAS signaling and colony formation in KRAS-driven cancer cells. (Structural note: (Blue: Cereblon ligand (HY-A0003), Black: linker; Pink: SOS1 binder SOS1 Ligand intermediate-3 (HY-161452)).
    LHF418
Cat. No. Product Name / Synonyms Application Reactivity
Ras Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.